The use of convalescent plasma collected from previously infected individuals to passively-transfer antibodies in order to protect or treat humans dates back almost 100 years, with some evidence for benefit against rabies, hepatitis B, polio, measles, influenza, Ebola and other pathogens. Today, convalescent plasma could provide short-medium term humoral immunity against COVID-19. The use of convalescent plasma is an interim approach, while vaccines and effective drug therapies are being developed. While the concept is simple, numerous steps are involved, and require cooperation between multiple entities, such as recovered patients who serve as donors; blood centers or other plasma collection centers; treating physicians and their patients; and health care administrators and regulators overseeing the safety of each step. Watch this webinar to learn about the collection of, regulation of, and treatment with convalescent plasma.
Moderator: Chancellor Donald, MD, Tulane University
Peter Marks, MD, PhD, U.S. Food and Drug Administration